Bio-Rad Laboratories (BIO-B) Common Equity (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Common Equity data on file, last reported at $6.9 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $6.9 billion, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 billion (up 2.57% YoY), and the FY2025 annual result was $7.5 billion, up 13.46% from the prior year.
• Common Equity retreated to $6.9 billion in Q1 2026 per BIO-B's latest filing, from $7.5 billion in the prior quarter.
• Over five years, Common Equity peaked at $10.2 billion in Q1 2022 and troughed at $6.6 billion in Q4 2024.
• A 5-year average of $8.1 billion and a median of $8.4 billion in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 44.71% in 2022, then advanced 13.46% in 2025.
• A 5-year view of Common Equity shows it stood at $9.6 billion in 2022, then decreased by 9.09% to $8.7 billion in 2023, then retreated by 24.85% to $6.6 billion in 2024, then advanced by 13.46% to $7.5 billion in 2025, then declined by 8.08% to $6.9 billion in 2026.
• Business Quant data shows BIO-B's Common Equity at $6.9 billion in Q1 2026, $7.5 billion in Q4 2025, and $6.7 billion in Q3 2025.